Our Clinical Candidate

Mocravimod is a S1P receptor modulator. Priothera is developing mocravimod with the aim of enhancing the curative potential of allo-HSCT. Promising early clinical results have revealed that mocravimod has the potential to decouple Graft-versus-Host Disease (GVHD) from Graft-versus-Leukemia (GVL), by preventing GvHD while preserving GvL.

Mocravimod binds to different S1P receptors with different affinities